Castration-Resistant Prostatic Cancer Clinical Trial
Official title:
PARABO - Pain Evaluation in Radium-223 (Xofigo®) Treated mCRPC Patients With Bone Metastases - a Non-interventional Study in Nuclear Medicine Centers
This observational prospective single arm cohort study is designed to assess pain and bone pain related quality of life of metastatic Castration Resistant Prostate Cancer (mCRPC) patients receiving Radium-223 in a real life nuclear medicine practice setting. In addition, overall survival, time to next tumor treatment (TTNT), time to first symptomatic skeletal event (SSE), course of blood counts, and safety will be assessed.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04116164 -
Safety and Targeting of Anti-hk2 Antibody in mCRPC
|
Early Phase 1 | |
| Not yet recruiting |
NCT04126915 -
Precise Therapy for mCRPC Patients Through Whole Exome Sequencing(PTtWES)
|
||
| Recruiting |
NCT04104607 -
the Bispecific PSMAxCD3 Antibody CC-1 in Patients With Castration Resistant Prostate Carcinoma
|
Phase 1 | |
| Recruiting |
NCT03016741 -
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
|
Phase 4 | |
| Active, not recruiting |
NCT05551117 -
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
|
Phase 2 | |
| Terminated |
NCT04404140 -
A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).
|
Phase 1 | |
| Recruiting |
NCT02998567 -
Combination Study of Guadecitabine/ASTX727 and Pembrolizumab
|
Phase 1 | |
| Active, not recruiting |
NCT03748641 -
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
|
Phase 3 | |
| Recruiting |
NCT05293496 -
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Available |
NCT06033001 -
Expanded Access Treatment With [Lu-177]-PNT2002 for Adult Patients With Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
|